ADMA Biologics (ADMA) Expected to Release Quarterly Earnings on Wednesday

ADMA Biologics (NASDAQ:ADMA) is anticipated to post its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to announce earnings of $0.1967 per share and revenue of $138.11 million for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:30 PM ET.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.16 earnings per share for the quarter, hitting the consensus estimate of $0.16. The firm had revenue of $124.39 million for the quarter, compared to the consensus estimate of $125.34 million. During the same quarter in the previous year, the company posted $0.14 EPS. The firm’s revenue was up 2.0% compared to the same quarter last year. On average, analysts expect ADMA Biologics to post $0.78 EPS for the current fiscal year and $0.85 EPS for the next fiscal year.

ADMA Biologics Price Performance

Shares of ADMA opened at $11.17 on Wednesday. The business has a 50-day moving average of $9.90 and a 200 day moving average of $11.13. ADMA Biologics has a fifty-two week low of $7.21 and a fifty-two week high of $20.46.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Mizuho dropped their price objective on shares of ADMA Biologics from $20.00 to $17.00 and set an “outperform” rating on the stock in a report on Wednesday, July 15th. Weiss Ratings reissued a “hold (c)” rating on shares of ADMA Biologics in a research report on Monday, September 14th. Finally, Zacks Research upgraded shares of ADMA Biologics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, September 2nd. Three equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, ADMA Biologics has an average rating of “Moderate Buy” and a consensus target price of $18.67.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company focused on developing, manufacturing and commercializing plasma-derived biologic products for people with compromised or weakened immune systems. The company’s activities include collecting human plasma, developing immune globulin therapies and manufacturing products for use in the prevention and treatment of certain infectious diseases.

ADMA’s portfolio includes Asceniv, an intravenous immune globulin indicated for primary humoral immunodeficiency disease, and Bivigam, an intravenous immune globulin used for the treatment of primary humoral immunodeficiency.